Research Ethics Reimagined

Disability, Inclusion, and Research Ethics With Nancy Olson, JD

25 min · 28 de abr de 2026
Portada del episodio Disability, Inclusion, and Research Ethics With Nancy Olson, JD

Descripción

In this episode of PRIM&R's podcast, "Research Ethics Reimagined," we explore the inclusion of individuals with disabilities in research with Nancy Olson, JD, IRB. Olson serves as an analyst at the University of Nebraska Medical Center and is the recipient of PRIM&R's 2024 Service Award. Drawing on more than two decades of experience in human research protections and her own lived experience as a person who became deaf, Olson discusses how assumptions about disability shape — and often limit — who gets to participate in research. She examines the responsibilities of both researchers and IRBs in designing accessible studies and calls for a shift from compliance-focused thinking to genuine participant-centered preparation.

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de Research Ethics Reimagined!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

23 episodios

episode The Science of Being Counted With David Dutwin, PhD artwork

The Science of Being Counted With David Dutwin, PhD

In this episode of PRIM&R’s podcast, "Research Ethics Reimagined," we explore the methodology, ethics, and future of public opinion research with David Dutwin, PhD, Executive Director and Senior Vice President of AmeriSpeak at NORC at the University of Chicago. Dr. Dutwin is a senior fellow with the program for opinion research and election studies at the University of Pennsylvania. He is a nationally recognized survey methodologist. For more than 20 years, he has taught courses in survey research and design, political polling, research methods, rhetorical theory, media effects, and other courses as an adjunct professor at the University of Pennsylvania, the University of Arizona, and West Chester University. He discusses how probability-based sampling underpins scientifically valid survey research, the safeguards that protect participants in sensitive surveys, and how artificial intelligence is reshaping the field.

27 de may de 202649 min
episode Disability, Inclusion, and Research Ethics With Nancy Olson, JD artwork

Disability, Inclusion, and Research Ethics With Nancy Olson, JD

In this episode of PRIM&R's podcast, "Research Ethics Reimagined," we explore the inclusion of individuals with disabilities in research with Nancy Olson, JD, IRB. Olson serves as an analyst at the University of Nebraska Medical Center and is the recipient of PRIM&R's 2024 Service Award. Drawing on more than two decades of experience in human research protections and her own lived experience as a person who became deaf, Olson discusses how assumptions about disability shape — and often limit — who gets to participate in research. She examines the responsibilities of both researchers and IRBs in designing accessible studies and calls for a shift from compliance-focused thinking to genuine participant-centered preparation.

28 de abr de 202625 min
episode The Promise and Perils of FDA’s New ‘Plausible Mechanism’ Pathway With Holly Fernandez Lynch, JD, MBe artwork

The Promise and Perils of FDA’s New ‘Plausible Mechanism’ Pathway With Holly Fernandez Lynch, JD, MBe

In this episode of PRIM&R's podcast, "Research Ethics Reimagined," we explore FDA's plausible mechanism pathway for ultra-rare genetic disorders with Holly Fernandez Lynch, Associate Professor of Medical Ethics at the University of Pennsylvania's Perelman School of Medicine. She discusses how this pathway enables personalized gene therapies for N-of-one or N-of-few diseases while raising important questions about regulatory process, evidence standards, and equitable access. Professor Fernandez Lynch also examines the remarkable case of baby KJ, who received a gene editor to treat his urea cycle disorder, and considers both the transformative potential and the procedural concerns surrounding FDA's approach.

20 de feb de 202649 min